Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO News In Brief: Hoechst Marion Roussel Anzemet

Executive Summary

Hoechst Marion Roussel Anzemet: Oral dolasetron mesylate for prevention of acute nausea and vomiting after moderately emetogenic platinum-containing chemotherapy may be optimal at 200 mg dose, according to dose-response data from a 307-patient trial presented at the American Society of Clinical Oncology meeting in Philadelphia May 18-21. The drug is administered 30 minutes prior to chemotherapy. A complete response rate of 73% was reported in the 200 mg dolasetron arm, compared to a 40% CR in the 25 mg arm; 61% of patients receiving 200 mg had no nausea versus 35% of those receiving 25 mg. An NDA for Anzemet was submitted in April...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel